Use of CtDNA for Monitoring of Stage III Colorectal Cancer

Sponsor
University of Pittsburgh
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02842203
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
Condition
Stage III Colorectal Cancer
Investigators
Robert Schoen, MD

See list of participating sites